Last reviewed · How we verify
PENNSAID Gel
PENNSAID is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation at the site of application.
PENNSAID is a topical nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation at the site of application. Used for Osteoarthritis pain of the knee, Osteoarthritis pain of other joints.
At a glance
| Generic name | PENNSAID Gel |
|---|---|
| Also known as | diclofenac sodium 2.0% w/w, Pennsaid topical 1.5% diclofenac, a non-steroid anti-inflammatory drug, Pennsaid 1.5%, Diclofenac sodium 1.5% topical solution |
| Sponsor | Mallinckrodt |
| Drug class | Topical NSAID |
| Target | COX-1 and COX-2 |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
The active ingredient is diclofenac, which penetrates the skin to reach underlying joint tissues and synovial fluid. By blocking COX-1 and COX-2 enzymes, it reduces prostaglandin production, thereby decreasing pain, inflammation, and swelling in osteoarthritis. The topical formulation allows local delivery while minimizing systemic exposure compared to oral NSAIDs.
Approved indications
- Osteoarthritis pain of the knee
- Osteoarthritis pain of other joints
Common side effects
- Application site reactions (erythema, pruritus, irritation)
- Photosensitivity
- Gastrointestinal effects (if systemic absorption occurs)
Key clinical trials
- Counterpain PXM Versus Diclofenac Versus Piroxicam (PHASE3)
- Comparison of the Effectiveness of Therapeutic Ultrasound and Phonophoresis in Chronic Low Back Pain (NA)
- Home-Based Strategies for Knee Osteoarthritis (NA)
- Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO) (PHASE2)
- A Real-World Evidence Study to Evaluate the Effects of Voltaren Use on Mobility and Quality of Life in Participants With Knee Osteoarthritis Pain (PHASE4)
- A Study to Evaluate Efficacy and Safety of AMZ001 for the Treatment of Knee Osteoarthritis Symptoms (PHASE3)
- Comparison of Diclofenac Systemic Exposure From Two Different Products (AMZ001 and Diclofenac Diethylammonium 1.16% Gel) in Healthy Participants After Repeated Topical Administrations for 7 Days. (PHASE1)
- To Check Dermatological Safety of Test Products by 24 Hours Patch Testing (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |